This page shows the latest Yasuchika Hasegawa news and features for those working in and with pharma, biotech and healthcare.
Campaign used graph indicating drug was superior to Pfizer’s Norvasc. Takeda's chief executive Yasuchika Hasegawa has admitted the company may have used "inappropriate" language in its marketing of blood ... The mis-marketing stemmed from a trial
Current president and CEO Yasuchika Hasegawa is expected to be named chairman and interim CEO at Takeda in June, but could hand over the reins within the following few months if ... 67-year-old Hasegawa started the search for a new CEO last year.
Yasuchika Hasegawa, president and CEO of Takeda, said: "Partnering the two organisations will have complementary effects and further increase our potential to become a truly global pharmaceutical company.".
Yasuchika Hasegawa, president of Takeda, said: "This additional indication for Amitiza will help Takeda further enhance our position in the US primary care and GI speciality markets.".
Other financial details were undisclosed. Yasuchika Hasegawa, president and CEO of Takeda, said: "We are delighted to have reached an agreement with one of the strongest global players in central nervous
More from news
Approximately 0 fully matching, plus 5 partially matching documents found.
firm. This will become effective from April 1 this year. He will take over from the long-standing Yasuchika Hasegawa, who will become the new chairman of the board. ... Weber, formerly of GlaxoSmithKline, said: “First, I would like to thank Yasuchika
He will lead the integration and leadership of the finance functions across Takeda and will report to the company's president and CEO Yasuchika Hasegawa. ... senior leadership team at Takeda,” said Hasegawa.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
No results were found
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...